AUTHORS
Jin Wang, PhD, McKenzie Patrick, PhD2, Junhua Lyu, PhD3, Yan Jin, PhD4, Hieu Vu, PhD5, Ju Wang, PhD6, Hui Cao7, Yuannyu Zhang8, Junmin Peng, PhD9, Min Ni, PhD10, Jian Xu, PhD11
AFFILIATIONS
1 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
2 University of Texas Southwestern Medical Center, Dallas, Texas, United States
3 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
8 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
ABSTRACT
The metabolism of branched-chain amino acids (BCAAs), including leucine, isoleucine, and valine, has emerged as an important metabolic dependency of acute myeloid leukemia (AML); however, whether genetically and clinically distinct AML subtypes exploit BCAA metabolism through shared or subtype-specific mechanisms remains largely unknown. Although BCAT1, the rate-limiting enzyme that initiates BCAA catabolism, is frequently overexpressed in AML, the molecular basis for its selective requirement and the metabolic fate of BCAAs during leukemogenesis are poorly understood.
Here, we systematically investigated BCAA metabolism across genetically distinct AML models driven by AML1-ETO (AE9a), FLT3-ITD, and MLL-AF9. Analysis of multiple AML patient cohorts revealed that BCAT1 is preferentially upregulated in AML1-ETO and FLT3-mutant AML, whereas its expression is substantially lower in MLL-rearranged leukemia. In contrast, expression of its paralog, BCAT2, remains largely unchanged across AML subtypes. To define the in vivo roles of BCAT1 in hematopoiesis and leukemogenesis, we generated hematopoietic-specific BCAT1 conditional knockout (Bcat1fl/fl) and knock-in overexpression (Bcat1LSL-OE) mouse models using CRISPR targeting, respectively. BCAT1 loss markedly delayed leukemia progression and prolonged survival in AE9a- and FLT3-ITD-driven AML, whereas BCAT1 overexpression accelerated leukemogenesis. In contrast, BCAT1 manipulation had minimal impact on MLL-AF9 leukemia, establishing BCAT1 as an AML subtype-specific metabolic dependency. Consistent with these findings, human AML cell lines with high BCAT1 expression were selectively sensitive to pharmacologic BCAT1 inhibition.
To investigate the underlying mechanism, we performed transcriptomic and quantitative proteomic analyses, revealing subtype-specific BCAA metabolic rewiring characterized by selective induction of the BCAA transporter LAT2 (encoded by SLC7A8) in BCAT1-dependent AE9a and FLT3-ITD leukemia. ChIP-seq analyses further support direct regulation of SLC7A8 by subtype-specific oncogenic transcription factors. Although LAT2 depletion significantly reduced intracellular leucine uptake, it had minimal impact on leukemia cell growth, indicating that enhanced BCAA transport alone does not explain BCAT1 dependency. To define the metabolic fate of BCAAs, we performed 13C6- and 15N-leucine isotope tracing. Compared with MLL-AF9 leukemia, AE9a and FLT3-ITD cells exhibited markedly increased flux of leucine carbon into TCA-cycle intermediates and non-essential amino acids, including glutamine and proline. In contrast, MLL-AF9 leukemia cells retained higher intracellular levels of labeled leucine, consistent with its role in sustaining mTORC1 signaling. Notably, 15N-leucine tracing revealed distinct utilization of BCAA as the nitrogen source, including elevated nitrogen disposal via the urea cycle in AE9a and FLT3-ITD leukemia, indicating that BCAT1-dependent AML utilizes the leucine carbon skeleton and amino-group transfer to support metabolism. Consistent with these metabolic differences, BCAT1-dependent AE9a and FLT3-ITD leukemia were enriched for DNA replication, ribosome biogenesis, and anabolic pathways, whereas BCAT1-independent MLL-AF9 AML preferentially elevated NF-κB, TNFα, and inflammatory signaling.
Together, our findings demonstrate that distinct AML oncogenic drivers establish subtype-specific metabolic programs that determine BCAT1 dependency. BCAT1-dependent AML preferentially channels BCAA-derived carbon and nitrogen to sustain leukemogenesis. These findings identify oncogene-specific BCAA metabolic rewiring as a fundamental mechanism underlying metabolic heterogeneity in AML and uncover subtype-selective metabolic vulnerabilities for therapeutic targeting.
DISCLOSURES
Jin Wang, PhD: No relevant conflicts of interest to declare.